Publications

Examining Phosphatidylethanol (PEth) Formation Rates Within and Between Subjects in Ex Vivo Whole Blood

Stark HG, Sanchez JJ, Hill-Kapturczak N, Roache JD, Ginsburg BC. Examining Phosphatidylethanol (PEth) Formation Rates Within and Between Subjects in Ex Vivo Whole Blood. Drug Test Anal. 2026 Apr 22. doi: 10.1002/dta.70079. Epub ahead of print. PMID: 42019969.

Spatial memory in Alzheimer’s disease 5XFAD mice is enhanced by XPO1 inhibitor KPT-330

Wong SQ, Ouellette A, Harrison L, McNamara A, Tam RA, Alexandrov A, Nawrocik-Madrid A, Sanchez JJ, Ginsburg BC, Andrade AA, Lapierre LR. Spatial memory in Alzheimer’s disease 5XFAD mice is enhanced by XPO1 inhibitor KPT-330. Geroscience. 2026 Feb 6. doi: 10.1007/s11357-026-02122-0. Epub ahead of print. PMID: 41652154.

Canagliflozin Reprograms the Aging Hippocampus in Genetically Diverse UM-HET3 Mice and Attenuates Alzheimer’s-Like Pathology. Aging Cell

Jayarathne H, Manchanayake DH, Sullivan R, Chimienti N, Kadri O, Gurdziel K, Kim S, Jang H, Ginsburg BC, Miller RA, Yakar S, Sadagurski M. Canagliflozin Reprograms the Aging Hippocampus in Genetically Diverse UM-HET3 Mice and Attenuates Alzheimer’s-Like Pathology. Aging Cell. 2025 Dec;24(12):e70255. doi: 10.1111/acel.70255. Epub 2025 Oct 5. PMID: 41047765; PMCID: PMC12686575.

Canagliflozin reprograms the aging hippocampus in genetically diverse UM-HET3 mice and attenuates Alzheimer’s-like pathology

Jayarathne H, Manchanayake DH, Chimienti N, Kadri O, Gurdziel K, Kim S, Jang H, Ginsburg BC, Miller RA, Yakar S, Sadagurski M. Canagliflozin reprograms the aging hippocampus in genetically diverse UM-HET3 mice and attenuates Alzheimer’s-like pathology. bioRxiv [Preprint]. 2025 Jun 15:2025.06.10.658747. doi: 10.1101/2025.06.10.658747. PMID: 40661442; PMCID: PMC12259070.

One month follow-up outcomes of a transdermal alcohol concentration-based contingency management intervention to reduce heavy drinking among driving while intoxicated arrestees

Hill-Kapturczak N, Lamb RJ, Roache JD, Moon TJ, Liang Y, Dougherty DM. One month follow-up outcomes of a transdermal alcohol concentration-based contingency management intervention to reduce heavy drinking among driving while intoxicated arrestees. Alcohol Clin Exp Res (Hoboken). 2025 May;49(5):1166-1176. doi: 10.1111/acer.70047. Epub 2025 Mar 31. PMID: 40165510; PMCID: PMC12097931.